Illustration: Allie Carl/Axios
Generate Biomedicines, a Flagship Pioneering-backed AI biotech, aims to raise as much as $425 million in an IPO.
Why it matters: Generate is going public as the biotech IPO market reopens unevenly, with mixed debut performances.
